{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T22:42:51Z","timestamp":1785451371320,"version":"3.56.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T00:00:00Z","timestamp":1638144000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T00:00:00Z","timestamp":1638144000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Steroid resistant nephrotic syndrome (SRNS), while uncommon in children, is associated with significant morbidity. Calcineurin inhibitors (CNIs) remain the first line recommended therapy for children with non-genetic forms of SRNS, but some children fail to respond to them. Intravenous (IV) cyclophosphamide (CTX) has been shown to be effective in Asian-Indian children with difficult to treat SRNS (SRNS-DTT). Our study evaluated the outcome of IV CTX treatment in North American children with SRNS-DTT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective review of the medical records of children with SRNS-DTT treated with IV CTX from January 2000 to July 2019 at our center. Data abstracted included demographics, histopathology on renal biopsy, prior and concomitant use of other immunosuppressive agents and serial clinical\/laboratory data. Primary outcome measure was attainment of complete remission (CR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eight children with SRNS-DTT received monthly doses (median 6; range 4\u20136) of IV CTX. Four (50%) went into CR, 1 achieved partial remission and 3 did not respond. Three of the 4 responders had minimal change disease (MCD). Excluding the 1 child who responded after the 4th infusion, the median time to CR was 6.5 (range 0.5\u20138) months after completion of IV CTX infusions. Three remain in CR at a median of 8.5\u2009years (range: 3.7\u201310.5\u2009years) after completion of CTX; one child relapsed and became steroid-dependent. No infections or life-threatening complications related to IV CTX were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>IV CXT can induce long term remission in North-American children with MCD who have SRNS-DTT.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-021-02605-6","type":"journal-article","created":{"date-parts":[[2021,11,28]],"date-time":"2021-11-28T21:02:37Z","timestamp":1638133357000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Intravenous cyclophosphamide induces remission in children with difficult to treat steroid resistant nephrotic syndrome from minimal change disease"],"prefix":"10.1186","volume":"22","author":[{"given":"Maha","family":"Haddad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arundhati","family":"Kale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lavjay","family":"Butani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,29]]},"reference":[{"issue":"4","key":"2605_CR1","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1080\/20469047.2017.1374003","volume":"37","author":"ML Downie","year":"2017","unstructured":"Downie ML, Gallibois C, Parekh RS, Noone DG. Nephrotic syndrome in infants and children: pathophysiology and management. Paediatr Int Child Health. 2017;37(4):248\u201358.","journal-title":"Paediatr Int Child Health"},{"issue":"10","key":"2605_CR2","doi-asserted-by":"publisher","first-page":"3055","DOI":"10.1681\/ASN.2016101121","volume":"28","author":"A Trautmann","year":"2017","unstructured":"Trautmann A, Schnaidt S, Lipska-Zietkiewicz BS, Bodria M, Ozaltin F, Emma F, et al. Long-term outcome of steroid-resistant Nephrotic syndrome in children. J Am Soc Nephrol. 2017;28(10):3055\u201365.","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"2605_CR3","first-page":"CD003594","volume":"2019","author":"ID Liu","year":"2019","unstructured":"Liu ID, Willis NS, Craig JC, Hodson EM. Interventions for idiopathic steroid-resistant nephrotic syndrome in children. Cochrane Database Syst Rev. 2019;2019(11):CD003594.","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"2605_CR4","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/S2352-4642(18)30283-9","volume":"2","author":"K Tullus","year":"2018","unstructured":"Tullus K, Webb H, Bagga A. Management of steroid-resistant nephrotic syndrome in children and adolescents. Lancet Child Adolesc Health. 2018;2(12):880\u201390.","journal-title":"Lancet Child Adolesc Health"},{"issue":"10","key":"2605_CR5","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1038\/ki.2012.238","volume":"82","author":"A Gulati","year":"2012","unstructured":"Gulati A, Sinha A, Gupta A, Kanitkar M, Sreenivas V, Sharma J, et al. Treatment with tacrolimus and prednisolone is preferable to intravenous cyclophosphamide as the initial therapy for children with steroid-resistant nephrotic syndrome. Kidney Int. 2012;82(10):1130\u20135.","journal-title":"Kidney Int"},{"issue":"1","key":"2605_CR6","doi-asserted-by":"publisher","first-page":"46","DOI":"10.4103\/ijn.IJN_240_16","volume":"28","author":"N Prasad","year":"2018","unstructured":"Prasad N, Manjunath R, Rangaswamy D, Jaiswal A, Agarwal V, Bhadauria D, et al. Efficacy and safety of cyclosporine versus tacrolimus in steroid and cyclophosphamide resistant nephrotic syndrome: a prospective study. Indian J Nephrol. 2018;28(1):46\u201352.","journal-title":"Indian J Nephrol"},{"issue":"1","key":"2605_CR7","first-page":"33","volume":"96","author":"S Supavekin","year":"2013","unstructured":"Supavekin S, Surapaitoolkorn W, Kurupong T, Chaiyapak T, Piyaphanee N, Pattaragarn A, et al. Tacrolimus in steroid resistant and steroid dependent childhood nephrotic syndrome. J Med Assoc Thail. 2013;96(1):33\u201340.","journal-title":"J Med Assoc Thail"},{"key":"2605_CR8","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3389\/fped.2019.00313","volume":"7","author":"R Topaloglu","year":"2019","unstructured":"Topaloglu R, Gulhan B, Celegen K, Inozu M, Hayran M, Duzova A, et al. Rituximab for children with difficult-to-treat Nephrotic syndrome: its effects on disease progression and growth. Front Pediatr. 2019;7:313.","journal-title":"Front Pediatr"},{"issue":"10","key":"2605_CR9","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1007\/s00467-017-3780-7","volume":"33","author":"MJ Kemper","year":"2018","unstructured":"Kemper MJ, Valentin L, van Husen M. Difficult-to-treat idiopathic nephrotic syndrome: established drugs, open questions and future options. Pediatr Nephrol. 2018;33(10):1641\u20139.","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"2605_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF00868243","volume":"8","author":"R Elhence","year":"1994","unstructured":"Elhence R, Gulati S, Kher V, Gupta A, Sharma RK. Intravenous pulse cyclophosphamide--a new regime for steroid-resistant minimal change nephrotic syndrome. Pediatr Nephrol. 1994;8(1):1\u20133.","journal-title":"Pediatr Nephrol"},{"issue":"12","key":"2605_CR11","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1007\/s00467-006-0276-2","volume":"21","author":"R Bhimma","year":"2006","unstructured":"Bhimma R, Adhikari M, Asharam K. Steroid-resistant nephrotic syndrome: the influence of race on cyclophosphamide sensitivity. Pediatr Nephrol. 2006;21(12):1847\u201353.","journal-title":"Pediatr Nephrol"},{"issue":"4","key":"2605_CR12","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s00467-003-1095-3","volume":"18","author":"A Bajpai","year":"2003","unstructured":"Bajpai A, Bagga A, Hari P, Dinda A, Srivastava RN. Intravenous cyclophosphamide in steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2003;18(4):351\u20136.","journal-title":"Pediatr Nephrol"},{"key":"2605_CR13","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1007\/s00467-020-04519-1","volume":"35","author":"A Trautmann","year":"2020","unstructured":"Trautmann A, Vivarelli M, Samuel S, Gipson D, Sinha A, Schaefer F, et al. IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2020;35:1529\u201361.","journal-title":"Pediatr Nephrol"},{"issue":"11","key":"2605_CR14","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1007\/s00467-003-1279-x","volume":"18","author":"HO Alshaya","year":"2003","unstructured":"Alshaya HO, Al-Maghrabi JA, Kari JA. Intravenous pulse cyclophosphamide--is it effective in children with steroid-resistant nephrotic syndrome? Pediatr Nephrol. 2003;18(11):1143\u20136.","journal-title":"Pediatr Nephrol"},{"issue":"2","key":"2605_CR15","doi-asserted-by":"publisher","first-page":"203","DOI":"10.5301\/JN.2011.6327","volume":"24","author":"TT Gargah","year":"2011","unstructured":"Gargah TT, Lakhoua MR. Mycophenolate mofetil in treatment of childhood steroid-resistant nephrotic syndrome. J Nephrol. 2011;24(2):203\u20137.","journal-title":"J Nephrol"},{"key":"2605_CR16","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1007\/s00467-020-04481-y","volume":"35","author":"P Ravani","year":"2020","unstructured":"Ravani P, Pisani I, Bodria M, Caridi G, Degl'Innocenti ML, Ghiggeri GM. Low-dose ofatumumab for multidrug-resistant nephrotic syndrome in children: a randomized placebo-controlled trial. Pediatr Nephrol. 2020;35:997\u20131003.","journal-title":"Pediatr Nephrol"},{"issue":"6","key":"2605_CR17","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1681\/ASN.2011080775","volume":"23","author":"A Magnasco","year":"2012","unstructured":"Magnasco A, Ravani P, Edefonti A, Murer L, Ghio L, Belingheri M, et al. Rituximab in children with resistant idiopathic nephrotic syndrome. J Am Soc Nephrol. 2012;23(6):1117\u201324.","journal-title":"J Am Soc Nephrol"},{"key":"2605_CR18","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jpeds.2018.01.008","volume":"197","author":"M Jellouli","year":"2018","unstructured":"Jellouli M, Charfi R, Maalej B, Mahfoud A, Trabelsi S, Gargah T. Rituximab in the management of pediatric steroid-resistant nephrotic syndrome: a systematic review. J Pediatr. 2018;197:191\u20137 e1.","journal-title":"J Pediatr"},{"issue":"6","key":"2605_CR19","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1681\/ASN.2012040413","volume":"23","author":"M Pradhan","year":"2012","unstructured":"Pradhan M, Furth S. Rituximab in steroid-resistant nephrotic syndrome in children: a (false) glimmer of hope? J Am Soc Nephrol. 2012;23(6):975\u20138.","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"2605_CR20","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1007\/s00467-009-1195-9","volume":"24","author":"MC Chaumais","year":"2009","unstructured":"Chaumais MC, Garnier A, Chalard F, Peuchmaur M, Dauger S, Jacqz-Agrain E, et al. Fatal pulmonary fibrosis after rituximab administration. Pediatr Nephrol. 2009;24(9):1753\u20135.","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"2605_CR21","doi-asserted-by":"publisher","first-page":"e00267","DOI":"10.1002\/prp2.267","volume":"5","author":"A Bonanni","year":"2017","unstructured":"Bonanni A, Bertelli E, Panicucci C, D'Alessandro M, Moscatelli A, Lampugnani E, et al. Ofatumumab-associated acute pneumonitis: not new but still the first case. Pharmacol Res Perspect. 2017;5(1):e00267.","journal-title":"Pharmacol Res Perspect"},{"issue":"5","key":"2605_CR22","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1016\/j.clinthera.2012.03.008","volume":"34","author":"H Li","year":"2012","unstructured":"Li H, Shi X, Shen H, Li X, Wang H, Li H, et al. Tacrolimus versus intravenous pulse cyclophosphamide therapy in Chinese adults with steroid-resistant idiopathic minimal change nephropathy: a multicenter, open-label, nonrandomized cohort trial. Clin Ther. 2012;34(5):1112\u201320.","journal-title":"Clin Ther"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-021-02605-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-021-02605-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-021-02605-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,28]],"date-time":"2021-11-28T21:02:51Z","timestamp":1638133371000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-021-02605-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,29]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2605"],"URL":"https:\/\/doi.org\/10.1186\/s12882-021-02605-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-842389\/v1","asserted-by":"object"}]},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,29]]},"assertion":[{"value":"24 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Institutional Review Board of the University of California Davis and deemed exempt from the need for written consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"395"}}